

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): August 6, 2026

vTv Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-37524
(Commission File No.)

47-3916571
(IRS Employer
Identification No.)

3980 Premier Drive, Suite 110
High Point, NC 27265
(Address of principal executive offices)

(336) 841-0300
(Registrant's telephone number, including area code)

NOT APPLICABLE
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.01 per share	VTVT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 6, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated August 6 2026, announcing financial results for the fiscal quarter ended June 30, 2026
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

VTV THERAPEUTICS INC.

By: /s/ Paul J. Sekhri

Name: Paul J. Sekhri

Title: President and Chief Executive Officer

Dated: August 6, 2026



vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026

Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D

HIGH POINT, N.C., August 6, 2026 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing *cadisegliatin*, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026. Based on its current cash position at the end of the second quarter of 2026, vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout. In the fourth quarter of 2026, the Company also plans to host a Key Opinion Leader (KOL) event focused on T1D, the burden of managing hypoglycemia without compromising glycemic control, and *cadisegliatin*'s potential to address this significant unmet need.

"*Cadisegliatin* has been specifically designed to address the significant unmet need of hypoglycemia, a major limiting factor in achieving optimal blood glucose control in T1D," said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. "We look forward to discussing *cadisegliatin*'s potential with leading experts in T1D at our planned fourth-quarter KOL event. With cash runway through our anticipated topline data readout, we are focused on advancing development of the potential first oral adjunctive therapy for people with T1D."

Recent Company Highlights

- **CATT1 Trial Advancing.** Enrollment in the ongoing Phase 3 CATT1 trial evaluating *cadisegliatin* as an oral adjunctive therapy to insulin in individuals with T1D is expected to be completed in the third quarter of 2026.
- **KOL Event on *Cadisegliatin* Program.** In the fourth quarter of 2026, the Company plans to host a KOL event focused on T1D, the significant unmet medical need of hypoglycemia, and the *cadisegliatin* Phase 3 clinical program.
- ***Cadisegliatin* Hybrid Closed-Loop Trial (Hybrid CATT1).** vTv expects to initiate the Phase 2a Hybrid CATT1 trial before year end 2026. This randomized, double-blind, crossover, multicenter study will evaluate *cadisegliatin* in T1D participants using hybrid closed-loop insulin delivery systems to inform the design and operational aspects of future Phase 3 research in this population.

Second Quarter 2026 Financial Results

- **Cash Position:** Cash and cash equivalents as of June 30, 2026, were \$86.6 million compared to \$88.9 million as of December 31, 2025.
- **Research & Development (R&D) Expenses:** R&D expenses were \$8.8 million and \$4.1 million for the three months ended June 30, 2026, and 2025, respectively. The increase was primarily driven by continued investment in the Phase 3 CATT1 trial.
- **General & Administrative (G&A) Expenses:** G&A expenses were \$5.2 million and \$3.6 million for the three months ended June 30, 2026, and 2025, respectively. The increase reflects ongoing support for corporate operations and clinical development activities.
- **Interest Income:** Interest income for the three months ended June 30, 2026, and 2025, of \$0.8 million and \$0.3 million, respectively, was related to dividend income from the Company's money market accounts.
- **Net Loss:** Net loss attributable to vTv shareholders for the three months ended June 30, 2026, was \$13.1 million or \$1.05 per basic and diluted share. Net loss attributable to vTv shareholders for the comparable period a year ago was \$6.0 million or \$0.92 per basic and diluted share.

Upcoming Events

- **H.C. Wainwright 28th Annual Global Investment Conference**
Format: Fireside Presentation and 1x1 Investor Meetings
Location: New York, NY
Date: September 14-16, 2026
- **5th Annual ROTH Healthcare Opportunities Conference**
Format: 1x1 Investor Meetings
Location: New York, NY
Date: September 29, 2026

vTv Therapeutics Inc.
Condensed Consolidated Balance Sheets
(in thousands)

	June 30, 2026	December 31, 2025
	(Unaudited)	
Assets		
Current assets:		
Cash and cash equivalents	\$ 86,643	\$ 88,932
Prepaid expenses	416	743
Other current assets	530	218
Total current assets	87,589	89,893
Other assets	4	6
Total assets	\$ 87,593	\$ 89,899
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued expenses	\$ 6,992	\$ 6,557
Warrant liability, related party	25	84
Total current liabilities	7,017	6,641
Contract liabilities	1,830	18,669
Warrant liability	114	152
Total liabilities	8,961	25,462
Commitments and contingencies		
Stockholders' equity:		
Class A Common Stock	39	39
Class B Common Stock	—	—
Additional paid-in capital	394,205	391,090
Accumulated deficit	(315,612)	(326,692)
Total stockholders' equity	78,632	64,437
Total liabilities and stockholders' equity	\$ 87,593	\$ 89,899

vTv Therapeutics Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
	(Unaudited)		(Unaudited)	
Revenue	\$ —	\$ —	\$ 36,839	\$ —
Operating expenses:				
Research and development	8,770	4,103	17,748	6,933
General and administrative	5,160	3,618	9,758	7,291
Total operating expenses	13,930	7,721	27,506	14,224
Operating (loss) income	(13,930)	(7,721)	9,333	(14,224)
Interest income	812	275	1,650	606
Other income (expense), net	64	66	97	21
Net (loss) income before income taxes and noncontrolling interest	(13,054)	(7,380)	11,080	(13,597)
Income tax provision	—	—	—	—
Net (loss) income before noncontrolling interest	(13,054)	(7,380)	11,080	(13,597)
Less: net loss attributable to noncontrolling interest	—	(1,334)	—	(2,459)
Net (loss) income attributable to vTv Therapeutics Inc.	\$ (13,054)	\$ (6,046)	\$ 11,080	\$ (11,138)
Net (loss) income attributable to vTv Therapeutics Inc. common shareholders	\$ (13,054)	\$ (6,046)	\$ 11,080	\$ (11,138)
Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock	\$ (1.05)	\$ (0.92)	\$ 0.89	\$ (1.69)
Basic weighted average number of vTv Therapeutics Inc. Class A common stock	12,409,316	6,587,070	12,409,297	6,584,969
Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock	\$ (1.05)	\$ (0.92)	\$ 0.76	\$ (1.69)
Diluted weighted average number of vTv Therapeutics Inc. Class A common stock	12,409,316	6,587,070	14,541,788	6,584,969

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by *cadisegliatin*, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In non-clinical studies, *cadisegliatin* acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether *cadisegliatin* can improve glycemic control through hepatic glucose uptake and glycogen storage. *Cadisegliatin* has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case,

their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of *cadisegliatin* to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact

John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Media Contact

Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com